[DOI] [PubMed] [Google Scholar] 37.Drucker D.J., Buse J.B., Taylor K., Kendall D.M., Trautmann M., Zhuang D., Porter L., DURATION-1 Study Group Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: A randomised, open-label, non-inferiority study
This aspect highlights the need for careful interpretation of experimental findings, particularly when activity is reported ( Weight of evidence: Overall evidence is Low given potential assay-interference and PK constraints
K.WrightA
We consolidate existing findings on the therapeutic potential of targeting the macrophage-ferroptosis axis, with a specific focus on oncological applications
Millikin, R
Similarly, an association was observed between GLP-1 RAs use and a lower risk of MAKEs, although it was less pronounced in patients with proteinuria and those receiving short-acting GLP-1 RAs